combination therapies with vemurafenib in braf v600e–mutant cancers
Published 1 year ago • 271 plays • Length 2:04Download video MP4
Download video MP3
Similar videos
-
1:26
novel treatment strategies for braf v600e-mutant nsclc
-
2:56
treating braf v600e-mutant nsclc with dabrafenib and trametinib
-
2:10
using biomarkers to predict response to combination therapies in braf-mutant melanoma
-
3:03
what is the importance of combination therapies for braf?
-
4:05
vemurafenib and cobimetinib in patients with braf-mutated melanoma
-
4:16
combination therapy in braf-mutant nsclc
-
3:05
dabrafenib and trametinib: a promising combination for the treatment of melanoma
-
3:08
os rates and prognostic categories for braf-mutated melanoma when treated with combination therapy
-
2:45
ulixertinib in tumors with braf fusions, non-v600e or non-v600k braf mutations
-
2:28
the evolving treatment paradigm for braf v600e-mutant mcrc
-
1:45
breakwater: encorafenib plus cetuximab in patients with braf v600e-mutant mcrc
-
9:24
anti-pd1 monotherapy or combination with ipi after braf/mek inhibitors in braf-mutant melanoma
-
3:53
targeted therapies for braf v600e-mutated mnsclc
-
2:10
combined treatment with braf and mek inhibitors in metastatic melanomas with braf mutations
-
10:08
perspectives on braf and mek inhibitor combinations in braf-mutant melanoma
-
5:14
braf mutations across cancers
-
0:54
dr. chapman on vemurafenib combination therapies
-
0:59
the success of the dabrafenib and trametinib combination in braf-mutated melanoma
-
2:58
role of braf mutation in the treatment for melanoma